3-(3,5-dimethylpyrazol-1-yl)-1-[3-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]azetidin-1-yl]propan-1-one
C25H25N5O3 — CID 91905492
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-(3,5-dimethylpyrazol-1-yl)-1-[3-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]azetidin-1-yl]propan-1-one
3-(3,5-dimethylpyrazol-1-yl)-1-[3-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]azetidin-1-yl]propan-1-one (PubChem CID 91905492) has the molecular formula C25H25N5O3 and a molecular weight of 443.51 g/mol. Its IUPAC name is 3-(3,5-dimethylpyrazol-1-yl)-1-[3-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]azetidin-1-yl]propan-1-one.
Molecular Properties
| Compound Name | 3-(3,5-dimethylpyrazol-1-yl)-1-[3-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]azetidin-1-yl]propan-1-one |
|---|---|
| PubChem CID | 91905492 |
| Molecular Formula | C25H25N5O3 |
| Molecular Weight | 443.51 g/mol |
| Exact Mass | 443.20 |
| IUPAC Name | 3-(3,5-dimethylpyrazol-1-yl)-1-[3-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]azetidin-1-yl]propan-1-one |
| SMILES | Cc1cc(C)n(CCC(=O)N2CC(Oc3ccc(-c4nc(-c5ccccc5)no4)cc3)C2)n1 |
| InChI | InChI=1S/C25H25N5O3/c1-17-14-18(2)30(27-17)13-12-23(31)29-15-22(16-29)32-21-10-8-20(9-11-21)25-26-24(28-33-25)19-6-4-3-5-7-19/h3-11,14,22H,12-13,15-16H2,1-2H3 |
| InChIKey | YABLNXIFPYTBKA-UHFFFAOYSA-N |
| XLogP | 3.90 |
| TPSA | 86.28 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 443.51 |
| LogP ≤ 5 | 3.90 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 91905492 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.